Over the last decades, the evolution in anti-retroviral therapy improved mortality and quality of life for human immunodeficiency (HIV)-positive patients. HIV has transitioned from a progressive and lethal disease to a chronic treatable process marked by a higher risk of comorbidities [ 1 , 2 ]. Particularly, cardiovascular diseases (CVD) are about twofold greater for people living with HIV (PLWH) compared with uninfected individuals. This includes an excess risk of myocardial infarction (MI), ischemic stroke, sudden cardiac death [ 3 ], heart failure (HF), pulmonary hypertension, and venous thrombosis [ 4 ]. The so-called “dual burden of disease” (PLWH with a greater CVD risk) represents a major worriment to public health worldwide [ 5 , 6 ].